Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:JNJ
  • CUSIP: 47816010
  • Web: www.jnj.com
Capitalization:
  • Market Cap: $343.54 billion
  • Outstanding Shares: 2,693,833,000
Average Prices:
  • 50 Day Moving Avg: $124.43
  • 200 Day Moving Avg: $119.53
  • 52 Week Range: $109.32 - $129.00
P/E:
  • Trailing P/E Ratio: 21.29
  • Foreward P/E Ratio: 16.63
  • P/E Growth: 2.78
Sales & Book Value:
  • Annual Revenue: $72.17 billion
  • Price / Sales: 4.76
  • Book Value: $26.10 per share
  • Price / Book: 4.89
Dividend:
  • Annual Dividend: $3.20
  • Dividend Yield: 2.6%
Profitability:
  • EBIDTA: $25.12 billion
  • Net Margins: 22.78%
  • Return on Equity: 25.61%
  • Return on Assets: 13.40%
Debt:
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 2.73%
  • Quick Ratio: 2.36%
Misc:
  • Average Volume: 6.10 million shs.
  • Beta: 0.74
  • Short Ratio: 2.31
 

Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Tuesday, May 30th will be paid a dividend of $0.84 per share on Tuesday, June 13th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Thursday, May 25th. This is a boost from Johnson & Johnson's previous quarterly dividend of $0.80. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.06. The company had revenue of $17.77 billion for the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. Johnson & Johnson's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.68 EPS. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017. View Earnings Estimates for Johnson & Johnson.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

17 brokerages have issued 1-year price targets for Johnson & Johnson's stock. Their predictions range from $112.80 to $145.00. On average, they anticipate Johnson & Johnson's share price to reach $130.68 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues.  While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
  • 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 14,370,293 shares, a decline of 17.4% from the April 13th total of 17,397,650 shares. Based on an average trading volume of 6,259,588 shares, the short-interest ratio is presently 2.3 days. Currently, 0.5% of the shares of the stock are sold short.

Who are some of Johnson & Johnson's key competitors?

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.28%), BlackRock Inc. (6.26%), State Street Corp (5.95%), State Farm Mutual Automobile Insurance Co. (1.40%), Bank of New York Mellon Corp (1.38%) and Wellington Management Group LLP (1.23%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nordea Investment Management AB, Pioneer Investment Management Inc., Boston Partners, Parametric Portfolio Associates LLC, Wellington Management Group LLP, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Swiss National Bank, Alliancebernstein L.P. and Karp Capital Management Corp. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Johnson & Johnson stock cost?

One share of Johnson & Johnson stock can currently be purchased for approximately $127.53.

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 10 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $130.68 (2.47% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/21/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/19/2017Morgan StanleyReiterated RatingEqual Weight$130.00 -> $135.00LowView Rating Details
5/19/2017Cowen and CompanyReiterated RatingBuy$138.00 -> $143.00LowView Rating Details
5/18/2017Stifel NicolausReiterated RatingHold -> Hold$124.00 -> $128.00LowView Rating Details
5/15/2017JPMorgan Chase & Co.UpgradeNeutral -> Overweight$123.64 -> $140.00HighView Rating Details
5/14/2017Jefferies Group LLCReiterated RatingHold$140.00 -> $135.00HighView Rating Details
4/17/2017Barclays PLCReiterated RatingEqual Weight$125.00 -> $130.00LowView Rating Details
1/26/2017Wells Fargo & CoDowngradeOutperform -> Market Perform$112.28 -> $112.80N/AView Rating Details
1/25/2017Royal Bank of CanadaLower Price TargetOutperform$133.00 -> $128.00N/AView Rating Details
1/25/2017Goldman Sachs Group IncLower Price TargetNeutral$120.00 -> $115.00N/AView Rating Details
12/20/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
11/28/2016Bank of America CorpReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00N/AView Rating Details
9/11/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00N/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00N/AView Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/18/2017        
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20171$1.86$1.86$1.86
Q3 20171$1.80$1.80$1.80
Q4 20171$1.59$1.59$1.59
Q1 20181$1.98$1.98$1.98
Q2 20181$2.04$2.04$2.04
Q3 20181$1.99$1.99$1.99
Q4 20181$1.78$1.78$1.78
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Next Dividend:6/13/2017
Annual Dividend:$3.20
Dividend Yield:2.51%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:54.42% (Trailing 12 Months of Earnings)
45.01% (Based on This Year's Estimates)
41.72% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.30%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
Source:
DateHeadline
marketbeat.com logoDrugmaker paying $33M over recalled nonprescription meds
marketbeat.com - May 24 at 6:06 PM
seekingalpha.com logoJ&J Is A Core Holding In The Pharmaceutical Space - Seeking Alpha
seekingalpha.com - May 24 at 6:04 PM
nasdaq.com logoJohnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2017 - Nasdaq
www.nasdaq.com - May 24 at 6:04 PM
finance.yahoo.com logoJ&J settles drug manufacturing probe by U.S. states for $33 mln
finance.yahoo.com - May 24 at 6:04 PM
finance.yahoo.com logoJohnson & Johnson Settles U.S. Drug Manufacturing Probe
finance.yahoo.com - May 24 at 6:04 PM
finance.yahoo.com logoThis Dividend Aristocrat is Going to Trade Ex-Dividend on May 25
finance.yahoo.com - May 24 at 11:22 AM
finance.yahoo.com logoNeupogen and Enbrel Could See Falling Revenues in 2017
finance.yahoo.com - May 24 at 11:22 AM
fool.com logo3 Top Dividend Stocks in the Dentistry Industry
www.fool.com - May 23 at 5:57 PM
seekingalpha.com logoJohnson & Johnson (JNJ) Presents at 2017 UBS Global Healthcare Conference - Company Conference Presentation Transcript
seekingalpha.com - May 23 at 5:37 PM
finance.yahoo.com logoHere's Why Alexion Pharma (ALXN) Stock is Sinking Today
finance.yahoo.com - May 23 at 5:37 PM
nasdaq.com logoEx-Dividend Reminder: Great Plains Energy, NextEra Energy and Johnson & Johnson
www.nasdaq.com - May 23 at 11:02 AM
prnewswire.com logoRisperdal Lawsuits Continue to Plague Johnson & Johnson, With More Than 16,000 Filings Nationwide, Bernstein Liebhard LLP Reports
www.prnewswire.com - May 22 at 5:31 PM
nasdaq.com logoAugust 18th Options Now Available For Johnson & Johnson (JNJ)
www.nasdaq.com - May 22 at 5:31 PM
fool.com logoThe 3 Best Dividend Stocks in Arthritis Medication
www.fool.com - May 22 at 9:25 AM
americanbankingnews.com logoJohnson & Johnson (JNJ) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - May 21 at 10:04 AM
fool.com logo3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market
www.fool.com - May 21 at 8:02 AM
prnewswire.com logoOperation Smile's 35th Anniversary presented by Johnson & Johnson
www.prnewswire.com - May 20 at 9:39 AM
americanbankingnews.com logoJohnson & Johnson (JNJ) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - May 20 at 8:18 AM
streetinsider.com logoJohnson & Johnson (JNJ) Near Deal to Sell Compeed for $1B - Source - StreetInsider.com
www.streetinsider.com - May 19 at 10:49 PM
seekingalpha.com logoJohnson & Johnson Lays Out Its Battle Plan
seekingalpha.com - May 19 at 5:48 PM
finance.yahoo.com logoUnderstanding J&J's Risk From New FDA Label Warning For Invokana
finance.yahoo.com - May 19 at 5:48 PM
americanbankingnews.com logoJohnson & Johnson (JNJ) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - May 19 at 10:52 AM
seekingalpha.com logoJ&J set for 19 data presentations at ASCO - Johnson & Johnson ... - Seeking Alpha
seekingalpha.com - May 19 at 10:37 AM
thestreet.com logoJohnson & Johnson Unit Sues to Block Sale of Copy of its Rheumatoid Arthritis Drug - TheStreet.com
www.thestreet.com - May 19 at 10:37 AM
finance.yahoo.com logoWhy Is Johnson & Johnson (JNJ) Up 4.4% Since the Last Earnings Report?
finance.yahoo.com - May 19 at 10:37 AM
finance.yahoo.com logoJohnson & Johnson Unit Sues to Block Sale of Copy of its Rheumatoid Arthritis Drug
finance.yahoo.com - May 19 at 10:37 AM
americanbankingnews.com logoJohnson & Johnson (JNJ) Upgraded at Vetr Inc.
www.americanbankingnews.com - May 19 at 12:46 AM
americanbankingnews.com logoJohnson & Johnson (JNJ) Price Target Raised to $128.00
www.americanbankingnews.com - May 18 at 9:54 AM
seekingalpha.com logoJohnson & Johnson: The Right Way To Play This Dividend Champion
seekingalpha.com - May 18 at 9:08 AM
finance.yahoo.com logoJohnson & Johnson offers EU concessions over Actelion deal
finance.yahoo.com - May 18 at 9:08 AM
fortune.com logoJohnson & Johnson Unveils Ambitious Multi-Billion Dollar Plan
fortune.com - May 17 at 6:04 PM
streetinsider.com logoJohnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting
www.streetinsider.com - May 17 at 6:04 PM
usatoday.com logoJohnson & Johnson aims for 10 billion-dollar drugs by 2021
www.usatoday.com - May 17 at 6:03 PM
finance.yahoo.com logoJohnson & Johnson plans to file for approval 10 potential blockbusters in next 4 years
finance.yahoo.com - May 17 at 6:03 PM
finance.yahoo.com logoJ&J CEO: We have to pay attention to out-of-pocket drug c...
finance.yahoo.com - May 17 at 6:03 PM
finance.yahoo.com logoThe world's largest drugmaker thinks it has 11 billion-dollar drugs in the pipeline — here's what they treat
finance.yahoo.com - May 17 at 6:03 PM
finance.yahoo.com logo[$$] Johnson & Johnson Faces FDA Headwind
finance.yahoo.com - May 17 at 6:03 PM
finance.yahoo.com logoJohnson & Johnson Execs Discuss Drug Pipeline
finance.yahoo.com - May 17 at 6:03 PM
finance.yahoo.com logoJohnson & Johnson analysts' day
finance.yahoo.com - May 17 at 6:03 PM
reuters.com logoFDA warns of foot, leg amputations with J&J diabetes drug - Reuters
www.reuters.com - May 17 at 9:49 AM
marketwatch.com logoJohnson & Johnson plans to file for approval 10 potential blockbusters in next 4 years - MarketWatch
www.marketwatch.com - May 17 at 9:49 AM
finance.yahoo.com logoJ&J's target: Launch or seek approval for 10 new medicines by 2021
finance.yahoo.com - May 17 at 9:49 AM
seekingalpha.com logoJohnson & Johnson updates investors today on extensive pipeline of drug candidates, 50+ regulatory filings expected by 2021
seekingalpha.com - May 17 at 7:26 AM
finance.yahoo.com logoU.S. FDA warns of foot, leg amputations with J&J diabetes drug
finance.yahoo.com - May 16 at 10:57 PM
fortune.com logoNew York County Sues Purdue Pharma and Johnson & Johnson Over Opioid Marketing - Fortune
fortune.com - May 16 at 5:57 PM
seekingalpha.com logoWhy You Should Feel Nervous If Johnson & Johnson Hits $140 - Seeking Alpha
seekingalpha.com - May 16 at 5:57 PM
marketwatch.com logoJohnson & Johnson's stock jumps after analyst turns bullish for first time in 4 years - MarketWatch
www.marketwatch.com - May 16 at 5:57 PM
thestreet.com logoWatch Johnson & Johnson Break Record Highs - TheStreet.com
www.thestreet.com - May 16 at 5:57 PM
finance.yahoo.com logoLilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes
finance.yahoo.com - May 16 at 5:57 PM
americanbankingnews.com logoInvestors Buy Large Volume of Put Options on Johnson & Johnson (JNJ)
www.americanbankingnews.com - May 16 at 12:26 PM

Social

Chart

Johnson & Johnson (JNJ) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff